Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS: Savannah Resources Jumps On Deal With Rio Tinto

Mon, 22nd Jun 2015 10:20

LONDON (Alliance News) - The following stocks are amongst the biggest risers and fallers within the main London indices midday Monday.
-------
FTSE 100 WINNERS
-------
Carnival, up 4.1% at 3,308 pence. Deutsche Bank upgrades Carnival to Buy from Hold, lifting its price target to 3,525p from 3,400p, with the bank saying it expects the second-quarter results from the cruiser operator to be above the upper end of the company's guidance. Analyst Richard Carter says he expects Carnival to demonstrate further booking and pricing recovery coupled with more operational momentum in its Carnival brand.

Sky, up 3.2%. Shares in the broadcaster are higher after the Murdoch family is reported to have rejected bids for its stake in Sky, stoking speculation that they intend to make a new attempt to take full control of the company, the Daily Telegraph reported on Saturday. The most recent bid is understood to have come from Vivendi, the French media conglomerate, while Vodafone Group also made an informal approach for the Murdoch's stake in Sky last year, the newspaper said.

Severn Trent, up 2.9% Canadian investment giant Borealis Infrastructure is considering a GBP5 billion approach for Severn Trent, two years after the FTSE 100 water company rejected an earlier takeover attempt, The Sunday Times reported. The newspaper, citing "sources close to the situation", said it is understood that the two sides opened talks last month, and discussions are at an early stage with no certainty a deal.

Capita, up 2.2%. The outsourcing company said that NHS England has named it as the preferred bidder to establish a single provider framework for administrative support functions for primary care across the UK. Capita said its selection includes an initial contract to manage and deliver services in England. The four-year sole provider framework has a maximum total value of GBP1 billion. Under the framework, the initial contract, which runs for seven to 10 years, for Capita to provide administrative support services for primary care in England is expected to be valued at up to about GBP400 million.
-------
FTSE 100 LOSERS
-------
Randgold Resources, down 1.8%, Fresnillo, down 0.7%. Precious metals miners are amongst the handful of FTSE 100 stocks which are trading lower Monday after the price of gold sunk below USD1,200 an ounce. Gold currently trades at USD1,195.35.
-------
FTSE 250 WINNERS
-------
Spire Healthcare Group, up 9.3%. The private healthcare provider said the major shareholder in South Africa-based private hospital group Mediclinic has acquired a 29.9% stake in the company for GBP432 million. The shareholder, Remgro, has acquired the stake in Spire at 360 pence per share. Spire shares closed at 320 pence on Friday. Spire said the intention is for Mediclinic to acquire the stake in Spire from Remgro in the "near future". Mediclinic and Remgro have confirmed they have no intention to acquiring the rest of Spire.

Bwin.Party Digital Entertainment, up 2.1%. The online gaming operator shares are higher after it said it has agreed to sell its entire interest in World Poker Tour to Ourgame International Holdings for USD35 million in cash. Bwin.party Digital Entertainment said it will continue to sponsor a number of World Poker Tour events and television shows in the US and Europe until the end of December 2016, and will have first refusal on any sponsorship opportunities that could become available until the end of December 2016.
-------
FTSE 250 LOSERS
-------
WS Atkins, down 1.4%. Panmure Gordon downgraded the project designer, engineer and management consultancy to Hold from Buy, saying the current share price does not reflect the near-term risks in its rail business.
-------
AIM ALL-SHARE WINNERS
-------
Savannah Resources, up 85%. The company said it has established a joint venture with mining giant Rio Tinto, which will result in both companies combining their heavy mineral sands projects in Mozambique. Under the deal, Savannah's Mutamba, Dongane and Jangamo prospects, together called the Jangamo project, will be combined with Rio Tinto's Chilubane project. Those prospects border one another and Savannah will operate the joint venture and have the ability to earn up to a 51% stake in the newly combined project by conducting the scoping, pre-feasibility and feasibility studies. Rio Tinto shares are up 0.3%.

Imaginatik, up 38%. The Consultancy and technology products company on Friday said it knows of no reason for the rise in its share price last week. However, it said it is aware that Quob Park Estates has been acquiring shares in the company. It added it has not received a notification of Quob's interest in its shares and has had no contact with the investment vehicle.

Lansdowne Oil & Gas, up 18%. The company said PSE Seven Heads and a subsidiary of PSE Kindsale Energy has entered into a contract with Diamond Offshore Drilling UK for the Ocean Guardian drilling rig to be used to drill a well at the Midleton Prospect in the North Celtic Sea. Kinsale Energy holds an 80% interest in the SEL 4/07 licence, with Lansdowne owning the remaining 20%. PSE Seven Heads is the operator of the licence.

ReNeuron Group, up 12%. The stem cell therapy company said it has extended its existing research collaboration with Australia-based Benitec Biopharma following positive results from early studies conducted by the pair.
-------
AIM ALL-SHARE LOSERS
-------
Armstrong Ventures, off 20%. The investment company said it is "hopeful" about the future, as it said it is operating against tough conditions, which it doesn't see improving in the near term. Chariman Haresh Kanabar said the general market conditions have been difficult for small AIM-listed companies focused on the resources and energy sectors.

Richland Resources, down 13%. The company said it will delay its first sapphire sale to the third quarter of 2015, news which follows a consultation with sightholders. Richland Resources, which is developing the Capricorn Sapphire project, said it will hold a product display and education session on its first recovered sapphires at the time of the Hong Kong Jewellery show from this coming Thursday to Sunday.

By Daniel Ruiz; danielruiz@alliancenews.com; and Neil Thakrar; neilthakrar@alliancenews.com; @NeilThakrar1

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
15 Apr 2014 12:23

ReNeuron leases building for relocation of business

AIM-listed ReNeuron has signed a deal with the Welsh government to lease a landmark building at Pencoed Technology Park, near Cardiff in South Wales. The stem cell therapy company explained that it will build a new state-of-the-art facility at Pencoed, to which it will relocate the business next ye

Read more
15 Apr 2014 10:01

ReNeuron Leases New Research & Development Facility With Welsh Government

LONDON (Alliance News) - Stem cell therapy company ReNeuron Group PLC said Tuesday that it had signed an agreement with the Welsh Government to lease a new research and development facility at the Pencoed Technology Park near Cardiff, South Wales. ReNeuron expects to begin to relocate its o

Read more
15 Apr 2014 07:50

UK MORNING BRIEFING: Aggreko Leads After Mixed Results

LONDON (Alliance News) - Aggreko is leading the FTSE 100 in early trading Tuesday after the temporary power company said it has seen mixed results in its first quarter, with strong underlying revenue growth in two of its three regions being impacted by adverse currency movements as previously exp

Read more
27 Mar 2014 13:48

UK MIDDAY BRIEFING: Regulators Confirm UK Energy Market Review

LONDON (Alliance News) - UK regulators have now confirmed they will investigate whether the country's major energy companies are preventing effective competition in the market, a decision that prompted British Gas parent Centrica to warn that the review could delay crucial investments in new i

Read more
27 Mar 2014 13:01

UK WINNERS & LOSERS: Babcock, Tullow Oil Lead Blue-Chip Fallers

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Thursday.

-------

FTSE 100 - WINNERS

Old Mutual, up 0.5%. The group has agreed to sell Skandia Germany and S

Read more
27 Mar 2014 11:13

ReNeuron Gets Approvals To Begin Two New Trials Using Stem Cell Product

LONDON (Alliance News) - ReNeuron Group PLC said Thursday that it has received final regulatory and ethical approvals to begin two new clinical trials using its CTXcyro stem cell product. The company will begin a Phase II clinical trial of its ReN001 investigational therapy in stroke disabi

Read more
14 Mar 2014 13:04

ReNeuron Eyes New UK Government Scheme Encouraging Novel Therapies

LONDON (Alliance News) - ReNeuron Group PLC Friday said it will look at whether the UK government's plan to launch a scheme to encourage the take up of novel therapies could be applied to its own therapeutic candidates. The scheme, called the Early Access to Medicines Scheme, is looking to

Read more
11 Mar 2014 12:48

US foundation funds ReNeuron stem cell therapy

A US-based charity has agreed to provide funding and access to clinical expertise for ReNeuron's retinal stem cell therapy candidate for a degenerative eye disease. Shares in ReNeuron rose 8.8% to 3.54p on the news. The Foundation for Fighting Blindess has agreed to provide further funding toward

Read more
11 Mar 2014 11:27

ReNeuron Retinal Stem Cell System Wins FFB Support

LONDON (Alliance News) - ReNeuron Group PLC said Tuesday its retinal stem cell therapy candidate is to receive support from a retinal research funding foundation. ReNeuron said its ReN003 retinal stem cell therapy candidate for the treatment of retinis pigmentosa is set to receive support

Read more
21 Jan 2014 10:04

ReNeuron Sees Positive Data For Stem Cells In Retinal Degeneration Test

LONDON (Alliance News) - ReNeuron Group PLC said Tuesday that a paper detailing the efficiency of its human retinal stem cells in a test model of retinal degeneration had been published in the Journal of Biological Chemistry. The test showed that ReNeuron's cells protected visual function w

Read more
21 Jan 2014 08:19

UK MORNING BRIEFING: Shares Higher; Unilever, SABMiller As Expected

LONDON (Alliance News) - UK shares have opened higher Tuesday, as Unilever and SABMiller have released results and trading statements in line with expectations.

Peel Hunt has issued ratings on the property sector, cutting Great Portland Est

Read more
13 Sep 2013 09:02

ReNeuron Moving All Therapeutic Programmes To Phase II Trials In Next 3 Years

Read more
22 Jul 2013 10:50

ReNeuron announces capital increase, funds to enter capital structure

Lifesciences group ReNeuron has announced that it has successfully raised 33m pounds in fresh funding to finance its research into stem-cell development, although it had to offer a small discount for the new equity. Significantly, three new investment funds are to enter its shareholder register with

Read more
28 May 2013 10:39

ReNeuron jumps on stem cell study results

Shares in AIM-listed stem cell business ReNeuron Group rose on Tuesday morning after the group unveiled details of progress with the PISCES clinical trial of its ReN001 stem cell therapy for disabled stroke patients. The group said that the primary aim of the study was to test the safety and toler

Read more
26 Mar 2013 09:45

ReNeuron Group to begin stem cell treatment of critical limb ischaemia

ReNeuron Group has received regulatory approval to begin the first phase of a clinical trial in the UK for the company's ReN009 stem cell therapy treatment for critical limb ischaemia. Critical limb ischaemia, a condition which leads to blood vessel blockage in limbs such as toes and can lead to am

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account